<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00639262</url>
  </required_header>
  <id_info>
    <org_study_id>07P.381</org_study_id>
    <secondary_id>2006-58</secondary_id>
    <nct_id>NCT00639262</nct_id>
  </id_info>
  <brief_title>Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors</brief_title>
  <official_title>Phase I Study of the Combination of Sorafenib and Radiation Therapy -/+ Temozolomide for the Treatment of Patients With Brain Metastases and Primary Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sorafenib™ has the potential to inhibit tumor growth, tumor angiogenesis , and enhance
      radiation response. This study will test the combination of Sorafenib™ and radiation therapy
      with or without temozolomide to determine tolerance of the combined treatments. Defining safe
      dosing of Sorafenib™ in this combination therapy will be achieved.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current standard of care for patients with brain metastatic malignancies is to receive
      radiation therapy alone, while the standard of care for patients with high grade primary
      brain malignancies, astrocytomas, is to receive to receive concurrent temozolomide with
      radiation therapy. In this phase I study, based on the range of efficacy of kinase inhibitors
      and its ability to cross the blood-brain barrier we will conduct two parallel studies. The
      first is to combine sorafenib and radiation therapy for the treatment of patients with brain
      metastases and the second is to combine sorafenib with temozolomide for primary brain tumors.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of Sorafenib</measure>
    <time_frame>30 days post-treatment</time_frame>
    <description>To determine the maximum tolerated dose (MTD) and a recommended phase II dose (RP2D) of Sorafenib and radiotherapy -/+ temozolomide patients with malignancies of the brain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>30 days post-treatment</time_frame>
    <description>Response rate (in those patients with measurable disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prediction of 1-year Recurrence</measure>
    <time_frame>1 year post-treatment</time_frame>
    <description>Determine if an increase in urinary VEGF and MMP levels, from the end of treatment to a patient's 1-month follow-up examination, is predictive of 1-year recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Toxicity of Sorafenib</measure>
    <time_frame>30 days post-treatment</time_frame>
    <description>To evaluate the safety and toxicity profile of Sorafenib in combination with radiation therapy -/+ temozolomide</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Brain Metastases</condition>
  <condition>Primary Brain Tumors</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - Brain Metastasis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib and Radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Gliomas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib and Radiotherapy, plus Temozolomide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib 200mg twice daily during XRT and 30 days after. (Sorafenib will be escalated for both cohorts to determine maximum tolerated dose)</description>
    <arm_group_label>Cohort 1 - Brain Metastasis</arm_group_label>
    <arm_group_label>Cohort 2 - Gliomas</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>For Cohort 2 - Gliomas only.</description>
    <arm_group_label>Cohort 2 - Gliomas</arm_group_label>
    <other_name>Temodar</other_name>
    <other_name>Temodal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiation Therapy (XRT)</description>
    <arm_group_label>Cohort 1 - Brain Metastasis</arm_group_label>
    <arm_group_label>Cohort 2 - Gliomas</arm_group_label>
    <other_name>XRT</other_name>
    <other_name>Radiation therapy</other_name>
    <other_name>radiation oncology</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients requiring a minimum 2-week course of radiation therapy

          2. Age &gt; or = 18

          3. All tumors of the central nervous system, or metastasis to the central nervous system.

          4. Measurable disease preferred but not required for eligibility

          5. Histologically or cytologically documented evidence of malignancy (for infratentorial
             and supratentorial glioma patients only).

          6. Radiographic evidence of brain metastasis

          7. ECOG performance status of 0 or 1

          8. Life expectancy of &gt; or = 3 months

        Exclusion Criteria:

          1. Patients receiving chemotherapy or other investigational drugs must be discontinued 14
             days prior to enrollment.

          2. Cardiac disease: Congestive heart failure &gt; class II NYHA. Patients must not have
             unstable angina (anginal symptoms at rest) or new onset angina (began within the last
             3 months) or myocardial infarction within the past 6 months.

          3. Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.

          4. Uncontrolled hypertension defined as systolic blood pressure &gt; 150 mmHg or diastolic
             pressure &gt; 90 mmHg, despite optimal medical management.

          5. Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.

          6. Active clinically serious infection &gt; CTCAE Grade 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Dicker, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.KimmelCancerCenter.org</url>
    <description>Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://www.JeffersonHospital.org</url>
    <description>Thomas Jefferson University Hospitals</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2008</study_first_submitted>
  <study_first_submitted_qc>March 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2008</study_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sorafenib</keyword>
  <keyword>Radiation Therapy</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Temozolomide</keyword>
  <keyword>Brain Metastases</keyword>
  <keyword>Brain Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

